Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.

Fond, Guillaume; Godin, O.; Schürhoff, Franck; Berna, Fabrice; Bulzacka, E.; Andrianarisoa, M.; Brunel, L.; Aouizerate, Bruno; Capdevielle, Delphine; Chéreau, Isabelle; Coulon, Nathalie; d’Amato, Thierry; Dubertret, Caroline; Dubreucq, Julien; Faget, Catherine; Lançon, Christophe; Leignier, Sylvain; Mallet, J.; Misdrahi, D.; Passerieux, Christine; Rey, R.; Schandrin, A.; Urbach, M.; Vidailhet, Pierre; Leboyer, Marion; Boyer, Laurent; Llorca, Pierre‐Michel

doi:10.1016/j.psychres.2018.09.024

Cited by 19 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies have suggested that psychiatric disorders, such as schizophrenia, alcoholism, and depression, may be associated with low serum levels of 25hydroxyvitamin D, 25(OH)D [7][8][9][10][11][12][13]. Recent studies report that vitamin D deficiency may be associated with an increase in depression rates from 8 to 14% [14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Contributions of vitamin D in the management of depressive symptoms and cardiovascular risk factors: study protocol for a randomized, double-blind, placebo-controlled clinical trial

Porto

Silva

Sougey

2019

Trials

View full text Add to dashboard Cite

AbstratofundoA depressão é uma das principais causas de incapacidade crônica em todo o mundo e um importante fator de risco cardiovascular, aumentando o risco relativo de doença arterial coronariana, bem como as taxas de morbimortalidade cardiovascular. Concomitantemente à alta prevalência de depressão, houve uma redução na exposição à luz solar com o aumento da urbanização e do uso de protetores solares, o que levou a uma redução nos níveis séricos de 25-hidroxivitamina D. Portanto, este artigo descreve uma protocolo para um ensaio clínico com o objetivo de avaliar os efeitos da suplementação de vitamina D na depressão e fatores de risco cardiovascular para contribuir com evidências sobre a influência potencial da suplementação na regulação do humor.MétodosEste estudo de protocolo foi orientado pelos itens de protocolo padrão: recomendações para ensaios intervencionistas. Um ensaio clínico randomizado, controlado por placebo, duplo-cego será realizado envolvendo 224 adultos (faixa etária de 18 a 60 anos) com depressão que estão tomando antidepressivos e não têm histórico de suplementação de vitamina D, comorbidades psiquiátricas, doença renal crônica, hipercalcemia, ou neoplasia. Os participantes serão recrutados nos ambulatórios psiquiátricos de duas universidades do nordeste do Brasil. Os participantes elegíveis que fornecerem consentimento por escrito serão designados aleatoriamente para o grupo de intervenção (n = 112; suplementação de vitamina D 50.000 UI por semana durante 6 meses) ou para o grupo controle (n = 112; placebo tomado semanalmente por 6 meses). Medidas para monitorar sintomas depressivos, exames clínicos e exames laboratoriais para avaliar fatores de risco cardiovascular e níveis séricos de vitamina D serão realizadas antes e após o período de intervenção.DiscussãoAté onde sabemos, este será o primeiro ensaio clínico com o objetivo de testar a eficácia da suplementação de vitamina D na redução do risco cardiovascular e como um adjuvante à terapia da depressão por um período prolongado (6 meses). Os resultados contribuirão para a compreensão dos efeitos terapêuticos da suplementação de vitamina D no tratamento da depressão e podem ajudar a orientar políticas públicas direcionadas à suplementação de vitamina para a redução do risco cardiovascular.Registro de testeRegistro Brasileiro de Ensaios Clínicos, RBR-6yj8sj/ Número Universal de Ensaios (UTN) U1111-1217-9237. Registrado em 23 de julho de 2018.

show abstract

Section: Introductionmentioning

confidence: 99%

Contributions of vitamin D in the management of depressive symptoms and cardiovascular risk factors: study protocol for a randomized, double-blind, placebo-controlled clinical trial

Porto

Silva

Sougey

2019

Trials

View full text Add to dashboard Cite

show abstract

“…In addition to tryptophan metabolism, phospholipid metabolism, pentose phosphate metabolism, and steroid hormone biosynthesis disturbance-related compounds, 25-hydroxyvitamin D2 was down-regulated by 1.82 times. A large decline of vitamin D2 was reported to be correlated with anxiety 45 . Vitamin D supplementation in rats helped to regulate and protect the dopamine system, and played a role in anti-anxiety 46 .…”

Section: Discussionmentioning

confidence: 99%

Anxiety disturbs the blood plasma metabolome in acute coronary syndrome patients

Jiang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Coronary heart disease (CHD) is the result of a complex metabolic disorder caused by various environmental and genetic factors, and often has anxiety as a comorbidity. Rupture of atherosclerotic plaque in CHD patients can lead to acute coronary syndrome (ACS). Anxiety is a known independent risk factor for the adverse cardiovascular events and mortality in ACS, but it remains unclear how stress-induced anxiety behavior impacts their blood plasma metabolome and contributes to worsening of CHD. The present study aimed to determine the effect of anxiety on the plasma metabolome in ACS patients. After receiving ethical approval 26 ACS patients comorbid anxiety were recruited and matched 26 ACS patients. Blood plasma samples were collected from the patients and stored at − 80 °C until metabolome profiling. Metabolome analysis was performed by liquid chromatography mass spectrometry (LC–MS), and the data were subjected to multivariate analysis. Disturbance of 39 plasma metabolites was noted in the ACS with comorbid anxiety group compared to the ACS group. These disturbed metabolites were mainly involved in tryptophan metabolism, pyrimidine metabolism, glycerophospholipid metabolism, pentose phosphate pathway, and pentose and glucuronate interconversions. The most significantly affected pathway was tryptophan metabolism including the down-regulation of tryptophan and serotonin. Glycerophospholipids metabolism, pentose and glucuronate interconversions, and pentose phosphate pathway were also greatly affected. These results suggest that anxiety can disturb three translation of material in ACS patients. Besides the above metabolism pathways pyrimidine metabolism was significantly disturbed. Based on the present findings the plasma metabolites monitoring can be recommended and may be conducive to early biomarkers detection for personalized treatment anxiety in CHD patients in future.

show abstract

“…The greatly decline of vitamin D2 has been reported to be related to anxiety. Supplementation of vitamin D to rats helps regulate and protect dopamine system, and plays the role in anti-anxiety 31,32 . Therefore, 25-hydroxy vitamin D2 supplementation maybe help to reduce anxiety.…”

Section: Discussionmentioning

confidence: 99%

Anxiety Disturbs Metabolome of Blood Plasma in Coronary Heart Disease Patients

Hong-yan

Jiang

et al. 2021

Preprint

View full text Add to dashboard Cite

Coronary heart disease (CHD) is the result of complex metabolic disorder caused by various environmental and genetic factors, and often comorbidity with anxiety. Anxiety was known to an independent risk factor for the adverse cardiovascular events and mortality in patients with CHD, while how stress-induced anxiety behavior impacts the metabolome of blood plasma in CHD patients and contributes to CHD worse is unclear. So this study aimed to investigate the effect of anxiety on metabolome of plasma in CHD patients. According to the inclusion and exclusion standard the blood plasma of CHD patients and CHD comorbidity with anxiety were collected after ethics approval. Metabolome analysis of blood plasma using liquid chromatography mass spectrometry (LC/MS) was performed, then multivariate data analysis was applied to evaluate the data. Disturbance of 39 plasma metabolites were altered in CHD patients accompany by anxiety patients as compared to control group. These disturbed metabolites were mainly involved in tryptophan metabolism, pyrimidine metabolism, glycerophospholipid metabolism, pentose phosphate metabolism, phenylalanine metabolism, pentose and glucuronate interconversions. The most significant pathway was tryptophan metabolism including the down-regulation of tryptophan and serotonin. In addition to tryptophan metabolism, the glycerophospholipids metabolism, pentose and glucuronate interconversions and pentose phosphate pathway were also greatly affected in this study. These results suggest that anxiety may further disturb CHD three translation of material metabolome. Besides theses metabolism pathway pyrimidine metabolism disturbed significantly which can aggravate the disease in patients with CHD. From these resoults the plasma metabolites monitoring was suggested to be recommended and may be conducive to early detect biomarkers to personalized treatment anxiety in patients with CHD in future.

show abstract

Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.

Abstract: Hypovitaminosis D is frequent and associated with depressive symptoms and anxiety disorders in schizophrenia. Vitamin D supplementation is associated with lower depressive and anxiety symptoms, however patients with hypovitaminosis D remain insufficiently treated.

Cited by 19 publications

References 44 publications

Contributions of vitamin D in the management of depressive symptoms and cardiovascular risk factors: study protocol for a randomized, double-blind, placebo-controlled clinical trial

Contributions of vitamin D in the management of depressive symptoms and cardiovascular risk factors: study protocol for a randomized, double-blind, placebo-controlled clinical trial

Anxiety disturbs the blood plasma metabolome in acute coronary syndrome patients

Anxiety Disturbs Metabolome of Blood Plasma in Coronary Heart Disease Patients

Contact Info

Product

Resources

About